Works about GEFITINIB

Results: 821
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring <bold>EGFR</bold> Mutations.

    Published in:
    Oncology, 2018, v. 95, n. 2, p. 109, doi. 10.1159/000488594
    By:
    • Nishinarita, Noriko;
    • Igawa, Satoshi;
    • Kasajima, Masashi;
    • Kusuhara, Seiichiro;
    • Harada, Shinya;
    • Okuma, Yuriko;
    • Sugita, Keisuke;
    • Ozawa, Takahiro;
    • Fukui, Tomoya;
    • Mitsufuji, Hisashi;
    • Yokoba, Masanori;
    • Katagiri, Masato;
    • Kubota, Masaru;
    • Sasaki, Jiichiro;
    • Naoki, Katsuhiko
    Publication type:
    Article
    10
    11
    12
    13
    14
    15

    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

    Published in:
    Oncologist, 2024, v. 29, n. 7, p. 596, doi. 10.1093/oncolo/oyae043
    By:
    • Pasello, Giulia;
    • Lorenzi, Martina;
    • Scattolin, Daniela;
    • Conte, Alessandro Del;
    • Cecere, Fabiana;
    • Pavan, Alberto;
    • Macerelli, Marianna;
    • Polo, Valentina;
    • Pilotto, Sara;
    • Santarpia, Mariacarmela;
    • Cumerlato, Enrico;
    • Ros, Valentina Da;
    • Targato, Giada;
    • Bortolami, Alberto;
    • Bonanno, Laura;
    • Ferro, Alessandra;
    • Maso, Alessandro Dal;
    • Frega, Stefano;
    • Guarneri, Valentina
    Publication type:
    Article
    16
    17
    18
    19

    From Diagnostic‐Therapeutic Pathways to Real‐World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR‐Positive Non‐Small Cell Lung Cancer (MOST Study).

    Published in:
    Oncologist, 2019, v. 24, n. 6, p. e318, doi. 10.1634/theoncologist.2018-0712
    By:
    • Pasello, Giulia;
    • Vicario, Giovanni;
    • Zustovich, Fable;
    • Oniga, Francesco;
    • Gori, Stefania;
    • Rosetti, Francesco;
    • Bonetti, Andrea;
    • Favaretto, Adolfo;
    • Toso, Silvia;
    • Redelotti, Roberta;
    • Santo, Antonio;
    • Bernardi, Daniele;
    • Giovanis, Petros;
    • Oliani, Cristina;
    • Calvetti, Lorenzo;
    • Gatti, Carlo;
    • Palazzolo, Giovanni;
    • Baretta, Zora;
    • Bortolami, Alberto;
    • Bonanno, Laura
    Publication type:
    Article
    20
    21
    22
    23
    24
    25

    A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.

    Published in:
    BMC Pharmacology & Toxicology, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s40360-022-00599-x
    By:
    • Nodehi, Reza Safaei;
    • Kalantari, Behjat;
    • Raafat, Jahangir;
    • Ansarinejad, Nafiseh;
    • Moazed, Vahid;
    • Mortazavizadeh, Seyed Mohammad Reza;
    • Hosseinzadeh, Mehran;
    • Ghaderi, Bayazid;
    • Jenabian, Arash;
    • Qadyani, Mojtaba;
    • Haghighat, Shirin;
    • Allahyari, Abolghasem;
    • Mirzania, Mehrzad;
    • Seghatoleslami, Mohammad;
    • Payandeh, Mehrdad;
    • Alikhasi, Afsaneh;
    • Kafi, Hamidreza;
    • Shahi, Farhad
    Publication type:
    Article
    26
    27
    28
    29

    Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 5, p. 532, doi. 10.1002/cpdd.427
    By:
    • Tan, Eng‐Huat;
    • Lim, Wan‐Teck;
    • Ahn, Myung‐Ju;
    • Ng, Quan‐Sing;
    • Ahn, Jin Seok;
    • Shao‐Weng Tan, Daniel;
    • Sun, Jong‐Mu;
    • Han, May;
    • Payumo, Francis C.;
    • McKee, Krista;
    • Yin, Wei;
    • Credi, Marc;
    • Agarwal, Shefali;
    • Jac, Jaroslaw;
    • Park, Keunchil
    Publication type:
    Article
    30
    31
    32
    33
    34

    Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

    Published in:
    Cancer Research & Treatment, 2024, v. 56, n. 1, p. 48, doi. 10.4143/crt.2023.453
    By:
    • Ki Hyeong Lee;
    • Byoung Chul Cho;
    • Myung-Ju Ahn;
    • Yun-Gyoo Lee;
    • Youngjoo Lee;
    • Jong-Seok Lee;
    • Joo-Hang Kim;
    • Young Joo Min;
    • Gyeong-Won Lee;
    • Sung Sook Lee;
    • Kyung-Hee Lee;
    • Yoon Ho Ko;
    • Byoung Yong Shim;
    • Sang-We Kim;
    • Sang Won Shin;
    • Jin-Hyuk Choi;
    • Dong-Wan Kim;
    • Eun Kyung Cho;
    • Keon Uk Park;
    • Jin-Soo Kim
    Publication type:
    Article
    35
    36
    37

    Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

    Published in:
    Cancer Research & Treatment, 2016, v. 48, n. 2, p. 458, doi. 10.4143/crt.2015.135
    By:
    • Jin Hyoung Kang;
    • Myung-Ju Ahn;
    • Dong-Wan Kim;
    • Eun Kyung Cho;
    • Joo-Hang Kim;
    • Sang Won Shin;
    • Xin Wang;
    • Jong Seok Kim;
    • Mauro Orlando;
    • Keunchil Park
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50